Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Other Accumulated Expenses (2018 - 2025)

Assembly Biosciences (ASMB) has 8 years of Other Accumulated Expenses data on record, last reported at $3.1 million in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses fell 35.82% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $3.1 million, down 35.82%, while the annual FY2024 figure was $6.9 million, 19.46% up from the prior year.
  • Other Accumulated Expenses reached $3.1 million in Q3 2025 per ASMB's latest filing, up from $1.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $6.9 million in Q4 2021 and bottomed at $1.7 million in Q2 2025.
  • Average Other Accumulated Expenses over 5 years is $3.8 million, with a median of $3.7 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: plummeted 54.51% in 2022, then skyrocketed 83.98% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $6.9 million in 2021, then tumbled by 54.51% to $3.1 million in 2022, then surged by 83.98% to $5.7 million in 2023, then grew by 19.46% to $6.9 million in 2024, then tumbled by 55.44% to $3.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $3.1 million in Q3 2025, $1.7 million in Q2 2025, and $2.3 million in Q1 2025.